OVer two years into the pandemic, a global emergency medicine professionals survey reveals that 62% reported one or more COVID-19-related burnout symptoms.
A group of researchers from Switzerland have visualised and catalogued "blueprints" that lead to defective proteins.
The successful phase III CheckMate 577 trial used adjuvant immunotherapy; a promising treatment for patients with recurrent oesophageal or upper gastric cancer.
A recent study describes the atomic-level working mechanism of the HCN4 channel, the 'pacemaker' protein that regulates the heart's rhythmic activity.
However well-intentioned physicians may be, they are often torn between incomprehension and a certain helplessness when dealing with precarious patients.
Transgender hormone treatments can be accompanied by difficult-to-treat dermatological changes in both trans women and trans men.
Sex reassingment poses challenges before, during, and after the transition. Patients should be accompanied by at least six medical specialties. This article takes a closer look at dermathological aspects.
The EMA considers that the benefit-risk balance of AstraZeneca's COVID-19 vaccine remains positive, and that, overall, there is no association with thromboembolic disorders.
Researchers have discovered that components of the biochemical pathway controlled by Wnt, a family of glycoproteins, could be a therapeutic target for antitumor compounds.
A study investigated the relationship between air pollution and new cases of asthma in children and adolescents. Current WHO air quality guideline for NO2 of 40 µg/m3 is set too high.
The media in German-speaking Switzerland have enthusiastically reported on a study suggesting that Echinaforce® could be effective against SARS-CoV-2, raising doubts in the scientific community.
Modern genetic testing methods improve the diagnosis of rare diseases. This is confirmed by a study in which over 7,000 rare diseases patients were examined and the entire genome was sequenced.
Research teams are increasingly trying to use the body's own immune system to fight cancer. A new study is helping to better understand the "arms race" between immune defenses and the disease, and may help improve modern therapeutic approaches.
Scientists studied the molecular evolution of tumors after exposure to genetically damaging chemicals. They discovered that the chemical-induced defects in individual DNA building blocks are not repaired immediately but are passed on over several rounds of cell division.
A retrospective cohort study of patients presenting with cardiotoxicity after treatment with fluoropyrimidines suggests that switching to S-1 (i.e. a combination of tegafur, gimeracil, and oteracil, at a molar ratio of 1:0.4:1) is safe for these patients and supports treatment continuation.
The first phase 3 study of pembrolizumab versus standard-of-care demonstrated superiority for first-line pembrolizumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.
At a 3-years median follow-up, the randomized, phase 3 EORTC 1325/KEYNOTE-054 trial demonstrated that adjuvant pembrolizumab taken for up to 1 year in high-risk stage III melanoma patients improved recurrence-free survival (RFS), with a consistent effect across subgroups.
Researchers are finding another approach to attack therapy-resistant tumors. If the hypoxia-induced factor-1α is switched off in natural killer (NK) cells, tumor growth slows down.
An overview of the ongoing trials and fresh knowledge that medicine has acquired on Huntington's disease was recently presented in Rome, Italy
Achalasia can be successfully managed with gentle endoscopic treatment. The method is as successful as a surgical intervention, previously considered the standard procedure for the condition.